Abstract:Antibody–drug Conjugates (ADCs) are a powerful therapeutic modality for cancer treatment. ADCs are multi-functional biologics in which a disease-targeting antibody is conjugated to an effector payload molecule via a linker. The success of currently used ADCs has been largely attributed to the development of linker systems, which allow for the targeted release of cytocidal payload drugs inside cancer cells. Many lysosomal proteases are over expressed in human cancers. They can effectively cleave a variety of peptide sequences, which can be exploited for the design of ADC linker systems. As a well-established linker, valine-citrulline-p-aminobenzyl carbamate (ValCitPABC) is used in many ADCs that are already approved or under preclinical and clinical development. Although ValCitPABC and related linkers are readily cleaved by cathepsins in the lysosome while remaining reasonably stable in human plasma, many studies have shown that they are susceptible to carboxylesterase 1C (Ces1C) in mouse and rat plasma, which hinders the preclinical evaluation of ADCs. Furthermore, neutropenia and thrombocytopenia, two of the most commonly observed dose-limiting adverse effects of ADCs, are believed to result from the premature hydrolysis of ValCitPABC by human neutrophil elastase. In addition to ValCitPABC, the GGFG tetrapeptidyl-aminomethoxy linker is also cathepsin-cleavable and is used in the highly successful ADC drug, DS8201a. In addition to cathepsin-cleavable linkers, there is also growing interest in legumain-sensitive linkers for ADC development. Increasing plasma stability while maintaining lysosomal cleavability of ADC linkers is an objective of intensive current research. This review reports recent advances in the design and structure–activity relationship studies of various peptide/peptidomimetic linkers in this field.

Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages

Use of a Cyclic α-Alkylidene-β-Diketone as a Cleavable Linker Strategy for Antibody-Drug Conjugates

Novel antibody-drug conjugate with UV-controlled cleavage mechanism for cytotoxin release

Nickel-Catalyzed Antibody Bioconjugation

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

NIR-II Light Leveraged Dual Drug Synthesis for Orthotopic Combination Therapy

Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases

Photocage Chameleon: Bond Scission by a Single Photon Above 800 nm

Uncialamycin-based antibody–drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect

Photocages Made to Order: Late-Stage Caging Protocol Enables Anti-Cancer Control with Near-Infrared Light

Light in a Heartbeat: Bond Scission by a Single Photon above 800 nm

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy

Ultralow-intensity NIR Light Triggered On-Demand Drug Release by Employing Highly Emissive UCNP and Photocleavable Linker with Low Bond Dissociation Energy

Nature-Inspired Photocatalytic Azo Bond Cleavage with Red Light.

Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Enzyme Prodrug Therapy with Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting Nanoparticles

A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in Antibodies

Alpha-Ammonium Carbamates Undergo Efficient Two-Step Linker Cleavage and Improve the Properties of Antibody Conjugates